For how we live.
In the TB-Speed project, trained nurses produced valid Xpert Ultra results in 99.6% to 100% of child samples and returned hospital results within three hours far more often than laboratories.
A run of CDC sole-source awards in August 2026 sends millions directly to the health ministries of Ethiopia, Zambia and Ukraine — a bet on host-government ownership of the HIV response by 2030.
External validation of the PAANTHER decision algorithm in 277 children across four African countries recorded 93.3% negative predictive value and 97.4% sensitivity against a composite reference standard.
In a prospective African validation, TB-detection AI matched radiologists but neither hit the WHO sensitivity target. In an Indian field programme, AI-led screening lifted case-finding sharply.
A trial in India found calling tuberculosis survivors was non-inferior to visiting them, on a combined measure. Split into survivors and their contacts, the picture reverses for the group at highest risk.
A six-month regimen for drug-resistant tuberculosis matched the standard of care in South Africa. Four days of antibiotics matched eight in African children hospitalised with severe pneumonia.
Most infections end when the immune system clears them. A few have evolved ways to hide, integrate or persist — which is why they can last a lifetime, and why 'cure' means something different for each.
Adult TB incidence and mortality are projected to fall 46% and 54% by 2030, short of the 80% and 90% goals. Wider symptom-driven testing matters most to closing the gap, the analysis suggests.
A systematic review of the Syrian crisis and infectious disease in Lebanon names overcrowding, poor sanitation and blocked healthcare access — not the presence of refugees themselves — as the reported drivers.
VPM1002 did not show non-inferiority to BCG for preventing tuberculosis infection in a phase 3 trial across sub-Saharan Africa. Far fewer infections occurred than planned, leaving the comparison unresolved.
A community study of 2,340 residents, run after the conflict that wrecked the region's health system, found presumptive tuberculosis above 10% in both town and countryside.
An all-oral short regimen, its length set by chest-imaging severity, was non-inferior to 18-month treatment and caused fewer serious adverse events in a Chinese randomised trial.
In a 122-patient South African proof-of-concept study, a four-month all-oral combination of quabodepistat, delamanid and bedaquiline cleared TB from sputum as often as the six-month standard.
An all-oral, bedaquiline-based programme treated 277 patients through six years of conflict in eastern Congo and reached 77.6% treatment success — above WHO's 75% mark — but mortality stayed at 13.4%.
The patient had spent months in Senegal and was found to carry the poultry-adapted virus alongside tuberculosis. WHO rates the public risk as low and traced no onward spread.
The estimate covers 2000 to 2023 and 108 countries. It is a counterfactual model, not a measured saving, and it lands as the US and other donors debate cutting the disease-specific funding it credits.
The Eighth Replenishment closed at US$12.64 billion against the US$18 billion its own Investment Case tied to 23 million lives saved and 400 million infections prevented by 2029.
The Lancet Global Health paper that produced this month's headline number also produced a larger one: 22.6 million additional deaths by 2030 if defunding deepens. The distinction matters more than the figure.
Washington intends to provide up to $792 million over five years. Malawi commits the rest — and the money is meant to flow through the government rather than NGOs.
Shared cell time raises transmission odds sharply — six months of it doubles them. But cell-level exposure explains only part of the genomic clustering, which undercuts contact tracing as a strategy.
WHO's Global Tuberculosis Report 2025 counts 10.7 million people ill and over 1.2 million dead last year. Available funding is US$5.9 billion against a US$22 billion annual target.
A TB vaccine financing plan, six target product profiles for children's cancer drugs, and a paediatric research agenda. All three are attempts to specify a product before a market decides to build it.
Across 165 clinics in four African countries, HIV testing fell by up to 35% and treatment starts by up to 32%. Most services had not returned to baseline two months after the orders were lifted.
IHME's annual accounting puts development assistance for health at less than half its 2021 peak, with no recovery forecast to 2030. A companion model estimates what that means for tuberculosis.
A Global Burden of Disease analysis of 204 countries finds 15.7 million children received no DTP dose in 2023, more than half of them in eight countries, and only one of three target vaccines on track for 2030.